Improving HoFH Outcomes: Strategies for Better Treatment and Reduced Barriers to Care

Program Description

Moderated by James A. Underberg, MD, MS, FACP, FNLA and featuring a panel with four faculty speakers (Linda Hemphill, MD, FACC, FNLA, FAHA, Robert Rosenson, MD, Seth Martin, MD, MHS, and Luba Burchett, RN, BSN) this 60 minute webcast will cover the following information: epidemiology of homozygous familial hypercholesterolemia (HoFH), signs and symptoms, diagnosis and identification of patients with HoFH, screening and genetic tests, currently available treatment options for patients, current guidelines for treatment, experience with evinacumab, navigating the treatment of women and children, and potential barriers to treatment.

Educational Objectives

Upon completion, participants should be able to:

• Identify the signs, symptoms, and diagnostic markers of familial hypercholesterolemia
• Describe current guidelines for the treatment of homozygous familial hypercholesterolemia (HoFH)
• Compare and contrast current treatment options for HoFH
• Formulate care strategies that incorporate patient needs and potential barriers to treatment

Intended Audience

Cardiologists, lipidologists, internists, primary care providers, infusion center nurses, and other healthcare providers who treat patients with HoFH.

Commercial Supporter

This activity is supported by an educational grant from Regeneron Pharmaceuticals.

Max Credits

• 1.00 / AMA PRA Category 1 Credit
• 1.00 / ANCC Contact Hour

Expires: April 14, 2023